2. UroToday Home
  3. Video Lectures

ASCO GU 2024 Videos

The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer - Nima Sharifi
April 25, 2024
Details
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
April 22, 2024
Details
NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay
March 26, 2024
Details
The STEEL Trial: Evaluating Enzalutamide Plus ADT with Salvage RT for High-Risk Recurrent Prostate Cancer - Edwin Posadas
March 14, 2024
Details
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston
March 13, 2024
Details
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
March 5, 2024
Details
CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George
March 5, 2024
Details
CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir
March 5, 2024
Details
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
March 5, 2024
Details
ARAMON Trial: Darolutamide Monotherapy and Testosterone Levels in Biochemically Recurrent Prostate Cancer - Andrew Laccetti
March 5, 2024
Details
Intravesical Erdafitinib (TAR-210) Demonstrates High Response Rates in NMIBC With Reduced Toxicity - Roger Li
March 4, 2024
Details
EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden
March 4, 2024
Details
Genetic Overlap Discovered Between Cancerous and Non-Cancerous Bladder Tissue in Small Study - Roger Li
March 4, 2024
Details
ANTICIPATE II Trial: APL-1202 and Tislelizumab for Neoadjuvant Bladder Cancer Treatment - Matthew Galsky
March 4, 2024
Details
Comprehensive Genetic Profiling May Optimize Targeted Therapy Selection for FGFR3-Mutated Urothelial Carcinoma Patients - Michael Basin
March 4, 2024
Details
The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams
March 1, 2024
Details
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
March 1, 2024
Details
Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo
March 1, 2024
Details
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam
March 1, 2024
Details
The Role of Nephrectomy with Immunotherapy in Metastatic Renal Cell Carcinoma - Dimitrios Makrakis
February 29, 2024
Details
Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon
February 29, 2024
Details
Update on Biomarkers in Renal Cell Carcinoma - David Braun
February 29, 2024
Details
LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad
February 29, 2024
Details
The De-Escalate Trial: Intermittently Stopping Prostate Cancer Treatments to Improve Quality of Life - Guillaume Grisay
February 28, 2024
Details
Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore
February 28, 2024
Details
BCG Shortage: What’s on the Horizon to Replace? - Joshua Meeks
February 28, 2024
Details
Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta
February 28, 2024
Details
Analyzing Real-World Impact of Race on ADT Mortality in Prostate Cancer - Judd Moul
February 27, 2024
Details
High-Risk Prostate Cancer: 80Gy + ADT Extends Survival Without Added Toxicity - Christophe Hennequin
February 27, 2024
Details
PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik
February 27, 2024
Details
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain
February 22, 2024
Details
Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell
February 22, 2024
Details
Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them? - Chana Weinstock
February 22, 2024
Details
KEYNOTE-564 Shows Overall Survival Benefit in Kidney Cancer with Pembrolizumab - Toni Choueiri
February 21, 2024
Details
CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal
February 21, 2024
Details
Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials - Cheryl Lee
February 21, 2024
Details
Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt
February 20, 2024
Details
Prostate Cancer Foundation's Guidelines for Black Men in the US - Isla Garraway
February 20, 2024
Details
Predicting Recurrence and Monitoring Response in BCG-Unresponsive NMIBC with Urinary Minimal Residual Disease Detection - Vikram Narayan
February 20, 2024
Details
The Efficacy and Resistance-Breaking Potential of EPI-7386 Masofaniten in Castration-Resistant Prostate Cancer - Andrew Laccetti
February 14, 2024
Details
Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand
February 7, 2024
Details
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
February 6, 2024
Details
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
February 2, 2024
Details